Meropenem B. Braun

Meropenem, the active ingredient in Meropenem B. Braun, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, meningitis, and sepsis in hospitalized patients.

GNH USA supplies Meropenem B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious infections affecting multiple organ systems.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication to resolve infection. - Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens causing infection. - Hospital‑acquired pneumonia: treats severe lung infection caused by multidrug‑resistant bacteria. - Ventilator‑associated pneumonia: offers effective coverage for ventilator‑related bacterial colonisation. - Severe sepsis and septic shock: delivers bactericidal activity to control systemic infection. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient cranial discomfort. - Phlebitis at injection site: local inflammation. - Elevated liver enzymes: mild hepatic enzyme rise.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe allergic reactions: including Stevens‑Johnson syndrome.

Clinicians should consider several safety measures before initiating therapy.

- Renal function: assess creatinine clearance and adjust dose in renal impairment. - Hepatic function: monitor liver enzymes during prolonged treatment. - Allergy history: avoid in patients with known carbapenem hypersensitivity. - Valproic acid co‑administration: may reduce serum valproate levels, monitor seizure control. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate concentrations, increasing seizure risk. - Probenecid: decreases renal clearance of meropenem, potentially raising toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may exacerbate renal impairment; adjust dosing as needed. - Warfarin: possible increase in INR; check coagulation parameters regularly.